FWIW, here's my take on these:
Biogen Idec (BIIB:Nasdaq - commentary - research) and Elan (ELN:NYSE - commentary - research): Antegren, multiple sclerosis, Nov. 25;
YES
SuperGen (SUPG:Nasdaq - commentary - research): Orathecin, pancreatic cancer, Nov. 26;
NO
United Therapeutics (UTHR:Nasdaq - commentary - research): Remodulin (intravenous formulation), pulmonary arterial hypertension, Nov. 30;
DON'T KNOW (D/K)
Sepracor (SEPR:Nasdaq - commentary - research): Estorra, insomnia, Dec. 15;
YES
Eyetech Pharmaceuticals (EYET:Nasdaq - commentary - research) and Pfizer (PFE:NYSE - commentary - research): Macugen, age-related macular degeneration, Dec. 17;
YES
Genzyme (GENZ:Nasdaq - commentary - research) and Bioenvision (BIVN:Nasdaq - commentary - research), Clofarabine, acute pediatric leukemia, Dec. 30;
D/K
OSI Pharmaceuticals (OSIP:Nasdaq - commentary - research) and Genentech (DNA:NYSE - commentary - research): Tarceva, non-small-cell lung cancer, Jan. 30, 2005. (OSI has said it expects approval decision to come earlier than Jan. 30, but the company is not any more specific.);
YES
American Pharmaceutical Partners (APPX:Nasdaq - commentary - research): Abraxane, breast cancer, Jan. 8, 2005;
??
Cyberonics (CYBX:Nasdaq - commentary - research): VNS Therapy System, depression, Jan. 31, 2005;
NO
Discovery Labs (DSCO:Nasdaq - commentary - research): Surfaxin, respiratory distress syndrome (pediatrics), Feb. 13, 2005;
YES
Amylin Pharmaceuticals (AMLN:Nasdaq - commentary - research): Symlin, diabetes, March 20, 2005. Exenatide, diabetes, April 30, 2005;
YES
Adolor (ADLR:Nasdaq - commentary - research): Entereg, post-operative ileus, April 25, 2005.
???
Clinical Data:
Celgene (CELG:Nasdaq - commentary - research): Revlimid, myelodysplastic syndrome phase II, Dec. 4-7, 2004;
GOOD
Atherogenics (AGIX:Nasdaq - commentary - research): AGI-1067, atherosclerosis, end of 2004;
GOOD???
Pharmos (PARS:Nasdaq - commentary - research): Dexanabinol, traumatic brain injury phase III, end of 2004;
GOOD???
Aphton (APHT:Nasdaq - commentary - research): Insegia, gastrointestinal cancer phase III, end of 2004;
GOOD???
Isis Pharmaceuticals (ISIS:Nasdaq - commentary - research):
Alifacorsen, Crohn's disease phase III, ulcerative colitis phase II, end of 2004;
D/K
Corgentech (CGTK:Nasdaq - commentary - research): E2F Decoy, peripheral bypass graft failure phase III, late fourth quarter 2004; E2F Decoy, coronary artery bypass graft failure phase III, early 2005;
???
Cell Therapeutics (CTIC:Nasdaq - commentary - research): Xyotax, nonsmall cell lung cancer phase III, first quarter 2005;
GOOD
Axonyx (AXYX:Nasdaq - commentary - research): Phenserine, Alzheimer's disease, phase II, first quarter 2005;
GOOD??
Encysive Pharmaceuticals (ENCY:Nasdaq - commentary - research): Thelin, pulmonary arterial hypertension phase III, February 2005;
GOOD
Onyx Pharmaceuticals (ONXX:Nasdaq - commentary - research): BAY 43-9006, renal cancer phase III interim analysis, first half 2005.
GOOD |
